KIT and chronic myelogenous leukemia, BCR-ABL1 positive: While Imatinib is a well-known inhibitor for various tyrosine kinases such as ABL1, ABL2, KIT, and PDGFR and has been used to treat chronic myelogenous leukemia and solid tumors, little is known about how it can affect intracellular bacterial infections9.